These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 29974233)

  • 41. A pilot, prospective, open-label simplification study to evaluate the safety, efficacy, and pharmacokinetics of once-daily lopinavir-ritonavir monotherapy in HIV-HCV coinfected patients: the MONOCO study.
    Cooper C; la Porte C; Tossonian H; Sampalis J; Ackad N; Conway B
    HIV Clin Trials; 2012; 13(4):179-88. PubMed ID: 22849960
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical impact of double protease inhibitor boosting with lopinavir/ritonavir and amprenavir as part of salvage antiretroviral therapy.
    Loutfy M; Raboud J; Thompson C; Tseng A; Abdurrahman Z; Kovacs C; Rachlis A; Phillips E; Rubin G; Gough K; Walmsley S
    HIV Clin Trials; 2003; 4(5):301-10. PubMed ID: 14583846
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Pharmaceutical care for severe and critically ill patients with COVID-19].
    Jiang S; Li L; Ru R; Zhang C; Rao Y; Lin B; Wang R; Chen N; Wang X; Cai H; Sheng J; Zhou J; Lu X; Qiu Y
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2020 May; 49(2):158-169. PubMed ID: 32391659
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lopinavir serum concentrations of critically ill infants: a pharmacokinetic investigation in South Africa.
    Schultheiß M; Kling S; Lenker U; von Bibra M; Rosenkranz B; Klinker H
    Med Microbiol Immunol; 2018 Nov; 207(5-6):339-343. PubMed ID: 29974233
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Pharmacokinetic profiles of lopinavir (LPV) in Chinese HIV-infected patients].
    Zhang X; Liu Z; Du X; Fu Q; Li T
    Zhonghua Nei Ke Za Zhi; 2015 May; 54(5):431-3. PubMed ID: 26080823
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Low dose lopinavir/ritonavir tablet achieves adequate pharmacokinetic parameters in HIV-infected Thai adolescents.
    Klinklom A; Puthanakit T; Gorowara M; Phasomsap C; Kerr S; Sriheara C; Ananworanich J; Burger D; Ruxrungtham K; Pancharoen C
    Antivir Ther; 2012; 17(2):283-9. PubMed ID: 22293065
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Plasma concentrations of the HIV-protease inhibitor lopinavir are suboptimal in children aged 2 years and below.
    Verweel G; Burger DM; Sheehan NL; Bergshoeff AS; Warris A; van der Knaap LC; Driessen G; de Groot R; Hartwig NG
    Antivir Ther; 2007; 12(4):453-8. PubMed ID: 17668553
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Therapeutic drug monitoring of boosted PIs in HIV-positive patients: undetectable plasma concentrations and risk of virological failure.
    Calcagno A; Pagani N; Ariaudo A; Arduino G; Carcieri C; D'Avolio A; Marinaro L; Tettoni MC; Trentini L; Di Perri G; Bonora S
    J Antimicrob Chemother; 2017 Jun; 72(6):1741-1744. PubMed ID: 28333285
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Are lopinavir and efavirenz serum concentrations in HIV-infected children in the therapeutic range in clinical practice?
    von Bibra M; Rosenkranz B; Pretorius E; Rabie H; Edson C; Lenker U; Cotton M; Klinker H
    Paediatr Int Child Health; 2014 May; 34(2):138-41. PubMed ID: 24225343
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety and pharmacokinetics of lopinavir in HIV/HCV coinfected patients with advanced liver disease.
    Casado JL; Del Palacio M; Moya J; Rodriguez JM; Moreno A; Perez-Elías MJ; Belso A; Dronda F; Moreno S
    HIV Clin Trials; 2011; 12(5):235-43. PubMed ID: 22180521
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A randomized clinical trial evaluating therapeutic drug monitoring (TDM) for protease inhibitor-based regimens in antiretroviral-experienced HIV-infected individuals: week 48 results of the A5146 study.
    Albrecht M; Mukherjee AL; Tierney C; Morse GD; Dykes C; Klingman KL; Demeter LM
    HIV Clin Trials; 2011; 12(4):201-14. PubMed ID: 22044856
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacokinetics and virological efficacy after switch to once-daily lopinavir-ritonavir in treatment-experienced HIV-1-infected children.
    Foissac F; Urien S; Hirt D; Frange P; Chaix ML; Treluyer JM; Blanche S
    Antimicrob Agents Chemother; 2011 Sep; 55(9):4320-5. PubMed ID: 21746952
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Therapeutic drug monitoring of antiretrovirals for people with HIV.
    Kredo T; Van der Walt JS; Siegfried N; Cohen K
    Cochrane Database Syst Rev; 2009 Jul; (3):CD007268. PubMed ID: 19588422
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Early initiation of lopinavir/ritonavir in infants less than 6 weeks of age: pharmacokinetics and 24-week safety and efficacy.
    Chadwick EG; Pinto J; Yogev R; Alvero CG; Hughes MD; Palumbo P; Robbins B; Hazra R; Serchuck L; Heckman BE; Purdue L; Browning R; Luzuriaga K; Rodman J; Capparelli E;
    Pediatr Infect Dis J; 2009 Mar; 28(3):215-9. PubMed ID: 19209098
    [TBL] [Abstract][Full Text] [Related]  

  • 55.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.